Oxford BioMedica PLC
LSE:OXB

Watchlist Manager
Oxford BioMedica PLC Logo
Oxford BioMedica PLC
LSE:OXB
Watchlist
Price: 619 GBX Market Closed
Market Cap: 745.9m GBX

Oxford BioMedica PLC
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Oxford BioMedica PLC
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Oxford BioMedica PLC
LSE:OXB
Operating Income
-ÂŁ30.7m
CAGR 3-Years
-20%
CAGR 5-Years
-19%
CAGR 10-Years
-9%
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Operating Income
-$201.1m
CAGR 3-Years
-9%
CAGR 5-Years
-109%
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Operating Income
-$285.7m
CAGR 3-Years
-41%
CAGR 5-Years
-48%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Operating Income
-ÂŁ70.5m
CAGR 3-Years
18%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Operating Income
ÂŁ68.6m
CAGR 3-Years
6%
CAGR 5-Years
8%
CAGR 10-Years
6%
Avacta Group PLC
LSE:AVCT
Operating Income
-ÂŁ29.6m
CAGR 3-Years
-3%
CAGR 5-Years
-15%
CAGR 10-Years
-25%
No Stocks Found

Oxford BioMedica PLC
Glance View

Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The company is headquartered in Oxford, Oxfordshire. The firm and its subsidiaries have developed lentiviral vector delivery system, LentiVector platform, which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, central nervous system (CNS) disorders and liver diseases. The firm's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401. The firm has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.

OXB Intrinsic Value
543.1 GBX
Overvaluation 12%
Intrinsic Value
Price

See Also

What is Oxford BioMedica PLC's Operating Income?
Operating Income
-30.7m GBP

Based on the financial report for Jun 30, 2025, Oxford BioMedica PLC's Operating Income amounts to -30.7m GBP.

What is Oxford BioMedica PLC's Operating Income growth rate?
Operating Income CAGR 10Y
-9%

Over the last year, the Operating Income growth was 54%. The average annual Operating Income growth rates for Oxford BioMedica PLC have been -20% over the past three years , -19% over the past five years , and -9% over the past ten years .

Back to Top